Targeted Drug Delivery

The ability to specifically target cancer while leaving healthy cells untouched has improved patient outcomes while minimizing toxic side effects and patient discomfort. We are developing targeted cancer therapies with the goals of increasing patient survival while decreasing toxicity. The Kelly lab is involved in all aspects of drug discovery from preclinical work to clinical translation.


Select Publications

  1. Dasa SS, Diakova G, Suzuki R, Mills AM, Gutknecht MF, Klibanov AL, Slack-Davis JK, Kelly KA. Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer. Theranostics. 2018;8(10):2782.
  2. Dasa SS, Suzuki R, Gutknecht M, Brinton LT, Tian Y, Michaelsson E, Lindfors L, Klibanov AL, French BA, Kelly KA. Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction. Journal of Controlled Release. 2015 Dec 28;220:556-67.
  3. Beech JR, Shin SJ, Smith JA, Kelly KA.  Mechanisms for targeted delivery of nanoparticles in cancer.  Curr Pharm Des. 2013; 19(37);6560-74.